Clinical ink announces GlucoseReady™
Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.
- Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.
- The suite of tools includes disease specific electronic clinical outcomes (eCOA) assessments, behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.
- Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.
- Jonathan Goldman MD FACC FRCP, CEO of Clinical ink commented: “The next generation of Cardiometabolic trials require a new approach to understanding who the patients are and what they care about.